• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    89 Biggest Movers From Friday

    6/21/22 4:44:52 AM ET
    $ADN
    $ADXN
    $AKRO
    $ALLK
    Industrial Machinery/Components
    Miscellaneous
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADN alert in real time by email

    Gainers

    • Revlon, Inc. (NYSE:REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
    • Grove Collaborative Holdings, Inc. (NYSE:GROV) rose 67.9% to close at $10.00. Grove Collaborative and Virgin Group Acquisition Corp. II announced the completion of their previously announced business combination.
    • Mereo BioPharma Group plc (NASDAQ:MREO) gained 62.5% to close at $1.30. AstraZeneca is rumored to be eyeing takeover of Mereo BioPharma Group, according to a report in The Times.
    • SoundHound AI, Inc. (NASDAQ:SOUN) climbed 49.8% to close at $4.44.
    • Swvl Holdings Corp. (NASDAQ:SWVL) gained 35.3% to settle at $6.90.
    • Clovis Oncology, Inc. (NASDAQ:CLVS) surged 31.9% to close at $1.18. Clovis Oncology recently announced a presentation detailing initial Phase 1 data from Phase 1/2 LuMIERE clinical study of FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286).
    • Jupiter Wellness, Inc. (NASDAQ:JUPW) jumped 31.4% to close at $0.80. Jupiter Wellness retired approximately 10% of its outstanding shares.
    • Satellogic Inc. (NASDAQ:SATL) jumped 29.6% to close at $5.04.
    • Electric Last Mile Solutions, Inc. (NASDAQ:ELMS) gained 29.4% to close at $0.3650 after jumping 100% on Thursday.
    • Sesen Bio, Inc. (NASDAQ:SESN) climbed 29.2% to close at $0.76.
    • Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) jumped 28.8% to close at $0.3002.
    • Virgin Orbit Holdings, Inc. (NASDAQ:VORB) gained 28.1% to close at $3.51.
    • Cipher Mining Inc. (NASDAQ:CIFR) gained 27.3% to settle at $1.82.
    • Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) gained 26.9% to close at $4.44. Comera was granted U.S. patent titled 'Excipient compounds for protein processing.'
    • Clear Channel Outdoor Holdings, Inc. (NYSE:CCO) jumped 26.6% to settle at $1.38.
    • Tivic Health Systems, Inc. (NASDAQ:TIVC) rose 26.3% to close at $2.40. Tivic Health Systems, during May, reported a Q1 loss of $0.23 per share.
    • Starry Group Holdings, Inc. (NYSE:STRY) gained 26% to close at $5.18. Cowen & Co. initiated coverage on Starry Group Holdings with an Outperform rating and announced a price target of $9.
    • XpresSpa Group, Inc. (NASDAQ:XSPA) gained 24.6% to close at $0.86.
    • Secoo Holding Limited (NASDAQ:SECO) rose 24% to settle at $0.2874. Secoo received approval to transfer to Nasdaq Capital Market.
    • Symbotic Inc. (NASDAQ:SYM) gained 23.8% to close at $16.80.
    • Altimmune, Inc. (NASDAQ:ALT) surged 22.9% to settle at $9.02.
    • Pharvaris N.V. (NASDAQ:PHVS) jumped 22.1% to close at $27.50.
    • Virco Mfg. Corporation (NASDAQ:VIRC) gained 21.9% to close at $3.67.
    • MINISO Group Holding Limited (NYSE:MNSO) climbed 21.8% to close at $7.67.
    • Sana Biotechnology, Inc. (NASDAQ:SANA) gained 21.5% to close at $5.15.
    • Jerash Holdings (US), Inc. (NASDAQ:JRSH) jumped 20.2% to settle at $6.70. Jerash Holdings’ board recently authorized a $3 million buyback.
    • Crexendo, Inc. (NASDAQ:CXDO) surged 20.1% to settle at $3.23.
    • Lyell Immunopharma, Inc. (NASDAQ:LYEL) jumped 20% to close at $5.46.
    • PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) rose 19.8% to close at $0.6201.
    • Zai Lab Limited (NASDAQ:ZLAB) jumped 19.8% to close at $27.73. Zai Lab recently announced breakthrough therapy designations granted for Repotrectinib in China.
    • Rocky Mountain Chocolate Factory, Inc. (NASDAQ:RMCF) jumped 19.6% to settle at $8.25. Rocky Mountain Chocolate, last month, posted Q4 EPS of $0.01.
    • Centessa Pharmaceuticals plc (NASDAQ:CNTA) gained 19.1% to close at $4.93 after BRMO Capital initiated coverage on the stock with an Outperform rating and $19 price target.
    • Sonder Holdings Inc. (NASDAQ:SOND) surged 18.8% to close at $1.52.
    • Helbiz, Inc. (NASDAQ:HLBZ) climbed 18.6% to close at $0.83.
    • REE Automotive Ltd. (NASDAQ:REE) jumped 18.6% to close at $1.53.
    • Rubius Therapeutics, Inc. (NASDAQ:RUBY) gained 18.4% to settle at $0.9323.
    • Lilium N.V. (NASDAQ:LILM) gained 18% to close at $2.69.
    • Heritage Global Inc. (NASDAQ:HGBL) jumped 17.8% to close at $1.55.
    • Cogent Biosciences, Inc. (NASDAQ:COGT) jumped 17.8% to close at $9.19. Cogent Biosciences recently announced a proposed public offering of $125 million of common stock.
    • Q&K International Group Limited (NASDAQ:QK) gained 17.7% to settle at $1.60.
    • Velocity Financial, Inc. (NYSE:VEL) rose 17.6% to close at $11.64.
    • BridgeBio Pharma, Inc. (NASDAQ:BBIO) gained 17.5% to close at $7.65.
    • Mersana Therapeutics, Inc. (NASDAQ:MRSN) jumped 17.5% to close at $3.70.
    • Akero Therapeutics, Inc. (NASDAQ:AKRO) surged 17.3% to settle at $12.16. Akero Therapeutics announced a $25 million equity investment by Pfizer at $9.90 per share.
    • Quotient Limited (NASDAQ:QTNT) gained 17.2% to settle at $0.3599.
    • Dyne Therapeutics, Inc. (NASDAQ:DYN) rose 17.2% to close at $5.94.
    • Synlogic, Inc. (NASDAQ:SYBX) surged 16.6% to close at $1.04.
    • Bit Digital, Inc. (NASDAQ:BTBT) jumped 16.4% to close at $1.42.
    • Allogene Therapeutics, Inc. (NASDAQ:ALLO) gained 16.4% to close at $ 10.96.
    • Allogene Therapeutics recently said that the FDA granted regenerative medicine advanced therapy designation to ALLO-501A for Large B Cell Lymphoma.
    • Stem, Inc. (NYSE:STEM) rose 16.4% to settle at $7.30.
    • bluebird bio, Inc. (NASDAQ:BLUE) shares gained 16.3% to close at $3.56. The FDA's Advisory Committee recently unanimously backed Bluebird bio’s gene therapy for a rare blood disorder.
    • Atara Biotherapeutics, Inc. (NASDAQ:ATRA) rose 16.2% to close at $5.87.
    • Scopus BioPharma Inc. (NASDAQ:SCPS) jumped 15.9% to settle at $0.4250.
    • Vaxart, Inc. (NASDAQ:VXRT) gained 15.6% to close at $3.12.
    • Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) jumped 15.3% to close at $7.62.
    • Allakos Inc. (NASDAQ:ALLK) gained 14.2% to close at $2.97.
    • Kinnate Biopharma Inc. (NASDAQ:KNTE) rose 13.7% to close at $9.36.
    • Seagen Inc. (NASDAQ:SGEN) shares rose 12.7% to close at $165.45. Merck is eyeing purchase of biotech Seagen, while other unnamed suitors are also eyeing Seagen, the Wall Street Journal said.
    • Calliditas Therapeutics AB (NASDAQ:CALT) rose 12% to close at $17.82.
    • Scholar Rock Holding Corporation (NASDAQ:SRRK) shares rose 10.9% to close at $5.39. Scholar Rock reported Phase 2 topaz trial extension data showing 'sizable and sustained motor function improvement at 24 months with apitegromab for non-ambulatory patients with types 2 and 3 spinal muscular atrophy.'
    • Sapiens International Corporation N.V. (NASDAQ:SPNS) climbed 10.9% to close at $23.22.
    • Sight Sciences, Inc. (NASDAQ:SGHT) jumped 10.4% to close at $8.27.
    • Surrozen, Inc. (NASDAQ:SRZN) gained 8.6% to close at $2.41. Surrozen recently initiated dosing in Phase 1 clinical trial of SZN-043 for severe alcoholic hepatitis.

     


    Losers

    • Renovare Environmental, Inc (NASDAQ:RENO) fell 64.7% to close at $0.06 on Friday.
    • Addex Therapeutics Ltd (NASDAQ:ADXN) shares declined 58.3% to settle at $1.50 after the company terminated its Phase 2b/3 study of Dipraglurant for dyskinesia associated with Parkinson's disease due to slow recruitment. The company suspended its guidance amid the termination.
    • ToughBuilt Industries, Inc. (NASDAQ:TBLT) fell 51.5% to close at $1.48 after the company priced a $6 million offering.
    • Advent Technologies Holdings, Inc. (NASDAQ:ADN) declined 27.6% to close at $2.89. Advent Technologies recently announced it received notification of euro 782.1 million of funding from the Greek State for the IPCEI Green HiPo project.
    • Bon Natural Life Limited (NASDAQ:BON) fell 23% to close at $2.85.
    • Axcella Health Inc. (NASDAQ:AXLA) dropped 22.7% to close at $1.80.
    • Pennsylvania Real Estate Investment Trust (NYSE:PEI) shares declined 20.5% to close at $4.23.
    • Sidus Space, Inc. (NASDAQ:SIDU) fell 19.3% to close at $6.16.
    • Equillium, Inc. (NASDAQ:EQ) declined 16.7% to settle at $1.75.
    • NeuroPace, Inc.(NASDAQ:NPCE) fell 16% to close at $5.03.
    • Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) dropped 15.7% to close at $2.42.
    • Innate Pharma S.A. (NASDAQ:IPHA) fell 15.3% to close at $2.00.
    • Applied UV, Inc. (NASDAQ:AUVI) declined 15.2% to close at $2.45.
    • AN2 Therapeutics, Inc. (NASDAQ:ANTX) fell 15.1% to settle at $8.51.
    • Neptune Wellness Solutions Inc. (NASDAQ:NEPT) declined 14.7% to close at $2.32. Neptune Wellness appointed Raymond Silcock as Chief Financial Officer.
    • Vertex Energy, Inc. (NASDAQ:VTNR) fell 14.5% to settle at $11.82.
    • Mesa Royalty Trust (NYSE:MTR) declined 14.5% to close at $14.96.
    • Northern Oil and Gas, Inc. (NYSE:NOG) fell 14.4% to close at $27.52.
    • Hillstream BioPharma, Inc. (NASDAQ:HILS) dropped 14.4% to close at $0.78.
    • Alvotech Ordinary Shares (NASDAQ:ALVO) fell 14.1% to close at $9.70.
    • Heart Test Laboratories, Inc. (NASDAQ:HSCS) dropped 14.1% to close at $2.0777. Heart Test Laboratories announced pricing of its IPO of 1.5 million units at a price of $4.25 per unit.
    • Athersys, Inc. (NASDAQ:ATHX) fell 12.9% to close at $0.2789 after dropping more than 12% on Thursday.
    • Calumet Specialty Products Partners, L.P. (NASDAQ:CLMT) declined 12.1% to close at $10.15.
    • Vivakor, Inc. (NASDAQ:VIVK) fell 10.4% to close at $2.23. Vivakor shares jumped 40% on Thursday after the company announced it signed a definitive agreement to acquire Silver Fuels Delhi and White Claw Colorado City.
    • Dream Finders Homes, Inc. (NASDAQ:DFH) dipped 10% to close at $10.64. B of A Securities downgraded Dream Finders Homes from Neutral to Underperform and lowered the price target from $18 to $10.5.
    • Range Resources Corporation (NYSE:RRC) fell 9.9% to close at $26.29.
    Get the next $ADN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADN
    $ADXN
    $AKRO
    $ALLK

    CompanyDatePrice TargetRatingAnalyst
    Calumet Inc.
    $CLMT
    4/24/2026$36.00Buy → Neutral
    Goldman
    Altimmune Inc.
    $ALT
    4/24/2026$2.50Sell → Neutral
    Goldman
    Equillium Inc.
    $EQ
    4/23/2026$7.00Outperform
    Oppenheimer
    Surrozen Inc.
    $SRZN
    4/21/2026Buy
    TD Cowen
    Scholar Rock Holding Corporation
    $SRRK
    4/21/2026$62.00Buy
    Canaccord Genuity
    Equillium Inc.
    $EQ
    4/16/2026$6.00Buy
    B. Riley Securities
    Allogene Therapeutics Inc.
    $ALLO
    4/16/2026Underweight → Neutral
    Analyst
    Equillium Inc.
    $EQ
    4/14/2026$6.00Strong Buy
    Raymond James
    More analyst ratings

    $ADN
    $ADXN
    $AKRO
    $ALLK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Calumet downgraded by Goldman with a new price target

    Goldman downgraded Calumet from Buy to Neutral and set a new price target of $36.00

    4/24/26 8:02:46 AM ET
    $CLMT
    Integrated oil Companies
    Energy

    Altimmune upgraded by Goldman with a new price target

    Goldman upgraded Altimmune from Sell to Neutral and set a new price target of $2.50

    4/24/26 7:59:47 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Equillium with a new price target

    Oppenheimer initiated coverage of Equillium with a rating of Outperform and set a new price target of $7.00

    4/23/26 7:55:51 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $ADXN
    $AKRO
    $ALLK
    SEC Filings

    View All

    SEC Form 144 filed by Dyne Therapeutics Inc.

    144 - Dyne Therapeutics, Inc. (0001818794) (Subject)

    4/24/26 4:47:05 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Dyne Therapeutics Inc.

    144 - Dyne Therapeutics, Inc. (0001818794) (Subject)

    4/24/26 4:46:22 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Dyne Therapeutics Inc.

    144 - Dyne Therapeutics, Inc. (0001818794) (Subject)

    4/24/26 4:45:59 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $ADXN
    $AKRO
    $ALLK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

    Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity

    11/25/24 8:41:11 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FDA Approval for RUBRACA issued to CLOVIS ONCOLOGY INC

    Submission status for CLOVIS ONCOLOGY INC's drug RUBRACA (SUPPL-13) with active ingredient RUCAPARIB CAMSYLATE has changed to 'Approval' on 12/21/2022. Application Category: NDA, Application Number: 209115, Application Classification: Efficacy

    12/22/22 4:37:40 AM ET
    $CLVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $ADXN
    $AKRO
    $ALLK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MINISO Announces Annual General Meeting on June 18, 2026 and Filing of Annual Report on Form 20-F

    GUANGZHOU, China, April 24, 2026 /PRNewswire/ -- MINISO Group Holding Limited (NYSE:MNSO, HKEX: 9896)) ("MINISO", "MINISO Group" or the "Company"), a global high-growth value retailer offering a variety of trendy lifestyle products featuring distinctive IP designs, today announced that it will hold an annual general meeting of the Company's shareholders (the "AGM") at 11:00 a.m. Beijing time on June 18, 2026 at Flats B-D, 35/F, Plaza 88, 88 Yeung Uk Road, Tsuen Wan, the New Territories, Hong Kong, for the purposes of considering and, if thought fit, passing each of the proposed resolutions set forth in the notice of the AGM (the "AGM Notice"). The AGM Notice, the ballot, the form of proxy an

    4/24/26 5:00:00 AM ET
    $MNSO
    Department/Specialty Retail Stores
    Consumer Discretionary

    Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

    Appointment strengthens Board's clinical development and regulatory expertise as Vaxart advances its oral vaccine platform SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced the appointment of James Breitmeyer, M.D., Ph.D., to its Board of Directors. Dr. Breitmeyer brings more than 35 years of biopharmaceutical experience, having led clinical development programs resulting in eight FDA product approvals and numerous regulatory successes across the United States, Europe, and Japan. "We are pleased to welcome Jim to t

    4/23/26 4:30:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model

    Ticker Symbol to Change from TIVC to VBIO Effective April 28, 2026; Company Advancing Entolimod™ Toward BARDA Funding and Strategic National Stockpile Procurement While Velocity Bioworks CDMO Builds Independent Revenue BaseSAN ANTONIO, April 23, 2026 /PRNewswire/ -- Tivic Health Systems, Inc. (NASDAQ:TIVC) today announced it is changing its corporate name to Valion Bio, Inc. and its Nasdaq ticker symbol from TIVC to VBIO, effective at market open on Tuesday, April 28, 2026. The CUSIP number for the company's common stock will remain unchanged. The rebrand is not merely cosmetic.

    4/23/26 4:05:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADN
    $ADXN
    $AKRO
    $ALLK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tcg Crossover Gp Ii, Llc bought $1,220,362 worth of shares (48,997 units at $24.91) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    3/16/26 7:05:51 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Posner Brian S bought $38,700 worth of shares (2,000 units at $19.35), increasing direct ownership by 17% to 13,500 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    3/13/26 4:46:19 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Posner Brian S bought $45,180 worth of shares (3,000 units at $15.06), increasing direct ownership by 35% to 11,500 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    3/10/26 5:33:53 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $ADXN
    $AKRO
    $ALLK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gibson Christopher converted options into 40,000 shares and sold $144,400 worth of shares (40,000 units at $3.61) as part of a pre-agreed trading plan (SEC Form 4)

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    4/24/26 4:23:14 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Burow Kristina exercised 89,800 shares at a strike of $9.14, increasing direct ownership by 426% to 110,871 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    4/24/26 4:05:11 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Schikan Johannes Gerardus Christiaan Petrus sold $213,382 worth of shares (7,100 units at $30.05) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 388,067 units (SEC Form 4)

    4 - Pharvaris N.V. (0001830487) (Issuer)

    4/24/26 2:09:35 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $ADXN
    $AKRO
    $ALLK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Clear Channel Outdoor Holdings Inc.

    SC 13D/A - Clear Channel Outdoor Holdings, Inc. (0001334978) (Subject)

    12/4/24 5:00:38 PM ET
    $CCO
    Advertising
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Rocky Mountain Chocolate Factory Inc.

    SC 13D/A - Rocky Mountain Chocolate Factory, Inc. (0001616262) (Subject)

    11/29/24 2:00:08 PM ET
    $RMCF
    Specialty Foods
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by Satellogic Inc.

    SC 13D/A - Satellogic Inc. (0001874315) (Subject)

    11/27/24 4:30:03 PM ET
    $SATL
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ADN
    $ADXN
    $AKRO
    $ALLK
    Leadership Updates

    Live Leadership Updates

    View All

    Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

    Appointment strengthens Board's clinical development and regulatory expertise as Vaxart advances its oral vaccine platform SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced the appointment of James Breitmeyer, M.D., Ph.D., to its Board of Directors. Dr. Breitmeyer brings more than 35 years of biopharmaceutical experience, having led clinical development programs resulting in eight FDA product approvals and numerous regulatory successes across the United States, Europe, and Japan. "We are pleased to welcome Jim to t

    4/23/26 4:30:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Heritage Global Valuations Appoints Elise DiBenedetto as Director of Business Development

    Heritage Global Valuations ("HGV"), a division of Heritage Global Inc. (NASDAQ:HGBL), a leading appraisal and liquidation firm, today announced the appointment of Elise DiBenedetto as Director of Business Development. Based in the Northeast, she will focus on expanding relationships across the restructuring, lending, and professional services sectors. In her role, DiBenedetto will be responsible for developing and strengthening relationships with financial institutions, private equity firms, restructuring advisors, and corporate clients. She will support HGV's delivery of valuation and asset advisory services in complex situations involving liquidity needs, restructurings, and asset monet

    4/2/26 2:00:00 PM ET
    $HGBL
    Real Estate

    Sapiens Selects Industry Leader as Chief Marketing Officer

    Sapiens hires accomplished B2B SaaS marketing executive Eva Skidmore as Chief Marketing Officer to accelerate AI-led growth LONDON, April 1, 2026 /PRNewswire/ -- Sapiens International Corporation N.V. (Sapiens) today announced that Eva Skidmore joins the company as the Chief Marketing Officer (CMO). She will lead the global Marketing team and be responsible for advancing the company's go-to-market (GTM) strategy and transformation. She will place AI at the core of Sapiens marketing strategy to transform how the company creates, activates, and scales demand while unifying Marketing, Sales, Product, and Partnerships into a single, intelligence-driven growth engine. This will enable Sapiens to

    4/1/26 6:30:00 AM ET
    $SPNS
    Computer Software: Prepackaged Software
    Technology

    $ADN
    $ADXN
    $AKRO
    $ALLK
    Financials

    Live finance-specific insights

    View All

    MINISO Group Chairman Proposes to Increase Shareholding

    GUANGZHOU, China, April 23, 2026 /PRNewswire/ -- MINISO Group Holding Limited (NYSE:MNSO, HKEX: 9896)) ("MINISO", "MINISO Group" or the "Company"), a global high-growth value retailer offering a variety of trendy lifestyle products featuring distinctive IP designs, today announced that the Company has been informed by Mr. Guofu Ye, the Chairman of the board of directors and Chief Executive Officer of the Company, that based on his confidence in the Company's value and long-term business prospects, he intends to increase his shareholding in the Company within 12 months commencing from the date of this press release by purchasing shares of the Company (including American Depositary Shares ("AD

    4/23/26 9:09:00 AM ET
    $MNSO
    Department/Specialty Retail Stores
    Consumer Discretionary

    Calumet, Inc. to Release First Quarter 2026 Earnings on May 8, 2026

    INDIANAPOLIS, April 23, 2026 /PRNewswire/ -- Calumet, Inc. (NASDAQ:CLMT) (the "Company," "Calumet," "we," "our" or "us"), announced today that it plans to report results for the First Quarter 2026 on May 8, 2026. A conference call to discuss the financial and operational results is scheduled for May 8th at 9:00 AM ET. Investors, analysts and members of the media interested in listening to the live presentation are encouraged to join a webcast of the call with accompanying presentation slides; parties interested in listening to the webcast may follow the link which will be made available at http://calumetspecialty.investorroom.com/events.  For those participants wishing to dial into the call,

    4/23/26 7:00:00 AM ET
    $CLMT
    Integrated oil Companies
    Energy

    Velocity Financial, Inc. Announces Date of First Quarter 2026 Financial Results Webcast and Conference Call

    Velocity Financial, Inc. (NYSE:VEL) ("Velocity" or "Company"), a leader in investor real estate loans, will release its first quarter 2026 results after the market close on Wednesday, May 6, 2026. Velocity's executive management team will host a conference call and webcast to review its financial results at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on the same day. Webcast Information The conference call will be webcast live in listen-only mode and can be accessed through the Events and Presentations section of the Company's Investor Relations website at https://www.velfinance.com/events-and-presentations. To join the webcast, please go to Velocity's website at least 15 minutes be

    4/22/26 8:30:00 AM ET
    $VEL
    Finance: Consumer Services
    Finance